NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology

Riddick, David S; Ding, Xinxin; Wolf, C Roland; Porter, Todd D; Pandey, Amit V; Zhang, Qing-Yu; Gu, Jun; Finn, Robert D; Ronseaux, Sebastien; McLaughlin, Lesley A; Henderson, Colin J; Zou, Ling; Flück, Christa E (2013). NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. Drug metabolism and disposition, 41(1), pp. 12-23. Bethesda, Md.: American Society for Pharmacology and Experimental Therapeutics 10.1124/dmd.112.048991

Full text not available from this repository. (Request a copy)

This is a report on a symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics and held at the Experimental Biology 2012 meeting in San Diego, California, on April 25, 2012. The symposium speakers summarized and critically evaluated our current understanding of the physiologic, pharmacological, and toxicological roles of NADPH-cytochrome P450 oxidoreductase (POR), a flavoprotein involved in electron transfer to microsomal cytochromes P450 (P450), cytochrome b(5), squalene mono-oxygenase, and heme oxygenase. Considerable insight has been derived from the development and characterization of mouse models with conditional Por deletion in particular tissues or partial suppression of POR expression in all tissues. Additional mouse models with global or conditional hepatic deletion of cytochrome b(5) are helping to clarify the P450 isoform- and substrate-specific influences of cytochrome b(5) on P450 electron transfer and catalytic function. This symposium also considered studies using siRNA to suppress POR expression in a hepatoma cell-culture model to explore the basis of the hepatic lipidosis phenotype observed in mice with conditional deletion of Por in liver. The symposium concluded with a strong translational perspective, relating the basic science of human POR structure and function to the impacts of POR genetic variation on human drug and steroid metabolism.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine

UniBE Contributor:

Pandey, Amit Vikram and Flück, Christa

ISSN:

0090-9556

Publisher:

American Society for Pharmacology and Experimental Therapeutics

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:40

Last Modified:

06 Dec 2013 13:38

Publisher DOI:

10.1124/dmd.112.048991

PubMed ID:

23086197

Web of Science ID:

000312903700002

Additional Information:

Riddick, David S;Ding, Xinxin;Wolf, C Roland;Porter, Todd D;Pandey, Amit V;Zhang, Qing-Yu;Gu, Jun;Finn, Robert D;Ronseaux, Sebastien;McLaughlin, Lesley A;Henderson, Colin J;Zou, Ling;Fluck, Christa E;AT005235/AT/NCCAM NIH HHS/;C4639/A5661/Cancer Research UK/United Kingdom;CA092596/CA/NCI NIH HHS/;ES007462/ES/NIEHS NIH HHS/;ES018884/ES/NIEHS NIH HHS/;GM082978/GM/NIGMS NIH HHS/;MOP-93759/Canadian Institutes of Health Research/Canada;R01 CA092596/CA/NCI NIH HHS/;Drug Metab Dispos. 2013 Jan;41(1):12-23. doi: 10.1124/dmd.112.048991. Epub 2012 Oct 19.

URI:

https://boris.unibe.ch/id/eprint/16090 (FactScience: 223665)

Actions (login required)

Edit item Edit item
Provide Feedback